Roneparstat

Next Previous
Drug Profile

Roneparstat

Alternative Names: SST 0001

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences
  • Class Antineoplastics; Heparins
  • Mechanism of Action Angiogenesis inhibitors; Heparinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 01 Nov 2016 Sigma Tau Research completes a phase I trial in Multiple myeloma (Second-line therapy or greater) in Germany, Israel and Italy (SC) (NCT01764880)
  • 01 Nov 2012 Phase-I clinical trials in Multiple myeloma in Israel (SC) (NCT01764880)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top